Government ❯ Regulatory Agencies ❯ FDA

Drug Approval

Mifepristone Psychedelic Drugs Mifepristone Regulations Safety Monitoring Supply Chain Management Opioid Test FDA Regulations Medicine Regulation Legal Challenges Safety Evaluation Public Health Leucovorin Approval Prescription Drugs Online Prescribing Services Risk Management Telehealth Regulations Safety Regulations Mifepristone Regulation Clinical Trials Vaccines MDMA Regulations

Hawley Seeks Congressional Oversight of Mifepristone After FDA Offers No Timeline on Safety Review

The move follows a private FDA briefing that offered no timeline for its safety review.

Republicans Push to Restore In‑Person Rules for Abortion Pill at Fiery Senate Hearing

FDA Halts Sales of Unapproved Ingestible Fluoride for Children 3 and Under

Cytokinetics Hit With Securities Class Action Over Aficamten Timeline Disclosures